报价延迟最少15分钟:2026/08/31 16:14 EDT
盘后时段
|
||||
|
5.69 
|
|
|
常规时段 (已结束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.69
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.41/-0.50
|
|
企业价值
1.95B
|
| 资产负债 |
|
每股账面净值
1.19
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
9.77M
|
|
每股收益
0.03
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system. |
